Skip to main content

Table 1 Clinical characteristics of the cohort according to patient groups including ICC-positive cell type status in bone marrow

From: Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information

  Resected cancers(n = 179) Advanced cancers(n = 33) Benign(n = 30)
Age, median [years] 69 (34–88) 63 (46–83) 69 (45–82)
Sex, male 92 (51.4%) 19 (57.6%) 21 (70.0%)
ICC-positivity: ≥ 1 ICC-positive cell / 2 × 106 MNC
 (ICC-status numbers may differ due to varying number of inconclusive ICC-results per category)
 TC 6/168 (3.6%) 2/31 (6.5%) 4/29 (13.8%)
 UIC 10/174 (5.7%) 0/31 (0.0%) 2/30 (6.7%)
 HC 16/169 (9.5%) 2/30 (6.7%) 3/29 (10.3%)
 QHC 12/135 (8.8%) 3/28 (7.9%) 3/25 (12.0%).
Preoperative Risk Factors
 CA19–9 ≥ 200kU/l 51/127 (40.2%); 52 missing 17/28 (60.7%); 5 missing 0/20; 10 missing
 Tumour size> 25 mm 71 (39.7%) 20 (60.6%) 10 (33.3%)
 Bilirubin > 50 μmol/L 132/151 (87.4%); 28 missing 21/32 (65.6%); 1 missing 7/29 (24.1%); 1 missing
Treatment
 Neoadjuvant chemotherapy GEMZ 6 (4.1%) FOLFIRINX 1 (0.7%) GEMZ 1 (3.0%) none
Operation    
 PPPD 146 (82.6%) BDB 24 (72.7%) 29 (96.7%)
 PD 25 (14.0%) Exp.lap. 9 (27.3%) 1 (3.3%)
 Pancreatectomy 8 (4.5%)   none
 Venous resection 49 (27.4%) n.a. 2 (6.7%)
 Adjuvant chemotherapy FLV: 91 (50.8%)GEMZ: 7 (3.9%)FLOX: 1 (0.7%)none: 80 (44.7%) Palliative chemotherapy31 (93.9%) n.a.
Histopathologic results
 Pancreatic cancer 101 (56.4%) 30  
 Malignant IPMN 9 (5.0%)   
 Distal bile duct ca. 31 (17.3%) 1  
 Ampullary cancer 21 (11.7%)   
 Duodenal cancer 17 (9.4%) 2  
 Pancreatobiliary type 146 (81.6%) 28 (84.8%) IPMN 11 (36.7%)
 Intestinal type 26 (14.5%) 5 (15.2%) ben.Tu. 5 (16.6%)
 Mucinous type 7 (3.9%)   AIP 6 (20.0%)
    chr.Panc 4 (13.3%)inflam. 4 (13.4%)
UICC-stage (V7): I 16 (10.6%)   
       II 150 (83.8%)   
       III 13 (7.3%) 7 (21.2%)  
       IV   26 (78.8%)  
N1-status 120 (67.0%)   
R1-status 87 (48.6%)   
Vascular infiltration 108 (60.3%)   
Perineural infiltration 141 (78.8%)   
  1. GEMZ Gemzitabine, FLV, FLOX, FOLFIRINOX Chemotherapy regimens; PD Pancreatico-duodenectomy, PPPD Pylorus preserving PD, BDB Biliodigestive bypass; Ex.lap. Explorative laparotomy; IPMN Intraductal pancreatic mucinous neoplasia; ben.tu. Benign tumour; AIP Autoimmune pancreatitis; chr. Panc. Chronic pancreatitis; inflam. Inflammation n.a. Not applicable; n.d. Not determined. Note: ICC-status numbers may differ due to varying number of inconclusive ICC-results per category
\